Here, weestablish an invitro model for BRCA2-crisis that demonstrates chromatin remodeling and activation of an NF-B survival pathway in response to transient BRCA2 depletion. View details for DOI 10.1200/JCO.22.01978. Women with BRCA1/2 mutations inherit high risks of breast and ovarian cancer; options to reduce cancer mortality include prophylactic surgery or breast screening, but their efficacy has never been empirically compared. These estimates can inform cancer testing and screening and improve clinical management strategies for women in the general population with inherited pathogenic variants in these genes. We studied the associations between HLA alleles and breast cancer risk using logistic regression, adjusting for population structure and age. Screening mammography has contributed to a significant increase in the diagnosis of ductal carcinoma in situ (DCIS), raising concerns about overdiagnosis and overtreatment. The proposed hybrid method integrates semantic term embedding with distributional semantics, producing a context-aware vector representation of unstructured mammography reports. This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to The communication behaviors of study participants who carry a gene mutation were analyzed 3 months after disclosure of genetic test results. Half (54.7%) used AIs only, 27.6% used tamoxifen only and 17.7% used both tamoxifen and AIs sequentially. This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of Ellisen, L., Kurian, A., Lincoln, S., Desmond, A., Mills, M., Shannon, K., Gabree, M., Anderson, M., Kobayashi, Y., Monzon, F., Ford, J. George Kurian, who grew up in Bengaluru, has just been appointed CEO of the $6-billion, US-based computer storage and data management company NetApp.As remarkable as that is, the more remarkable part of this story is the near identical journeys that George and his twin brother Thomas Kurian, president of Oracle, have had. These results suggest disparities in the care of patients from SGM groups and warrant further study to inform interventions. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. Annual MRI starting at 30 years followed by mammography and MRI at 40 years was estimated to reduce mortality by 55.4% (55.3%-55.4%) to 59.5% (58.5%-60.4%), with 5075 (5057-5093) to 5415 (5393-5437) false-positive screenings and 1439 (1429-1449) to 1528 (1517-1538) benign biopsies per 1000 women. Difficulty of access to cascade testing, particularly for family members that do not live in the United States, was also of concern. The common core of parameters includes population rates of births and deaths; age- and cohort-specific temporal rates of breast cancer incidence in the absence of screening and treatment; effects of risk factors on incidence trends; dissemination of plain film and digital mammography; screening test performance characteristics; stage or size distribution of screen-, interval-, and clinically- detected tumors by age; the joint distribution of ER/HER2 by age and stage; survival in the absence of screening and treatment by stage and molecular subtype; age-, stage-, and molecular subtype-specific therapy; dissemination and effectiveness of therapies over time; and competing non-breast cancer mortality.In this paper, we summarize the methods and results for the common input values presently used in the CISNET breast cancer models, note assumptions made because of unobservable phenomena and/or unavailable data, and highlight plans for the development of future parameters.These data are intended to enhance the transparency of the breast CISNET models. To quantify the influence of RS assay on changing chemotherapy plans in a general practice setting using causal inference methods.We surveyed 3880 newly diagnosed breast cancer patients in Los Angeles and Georgia in 2013-14. To examine the temporal trajectory of insurance coverage for next-generation tumor sequencing (sequencing) by private US payers, describe the characteristics of coverage adopters and nonadopters, and explore adoption trends relative to the Centers for Medicare and Medicaid Services' National Coverage Determination (CMS NCD) for sequencing.We identified payers with positive coverage (adopters) or negative coverage (nonadopters) of sequencing on or before April 1, 2019, and abstracted their characteristics including size, membership in the BlueCross BlueShield Association, and whether they used a third-party policy. Social determinants and lifestyle factors may explain some of the survival disparities for ER/PR+ BC.Addressing these factors may help reduce the higher mortality of African American women with ER/PR+ BC. SM use for coping was associated with lower QOL (p, View details for DOI 10.1007/s11764-020-00959-8. High-risk lesions that were screen detected by MRI in three women included radial scars and atypical lobular hyperplasia. We analyzed DNA samples for single-nucleotide polymorphisms reported to modify breast cancer risk. These patients received germline testing between January 5, 2015, and January 31, 2020, although most (81% of patients) received testing between January 2, 2018, and January 31, 2020.The prevalence of pathogenic germline variants (PGVs) was calculated by gene, cancer type, and age at diagnosis. Eleven genes (ATM, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, NBN, STK11, RAD51C, and RAD51D) were associated with ovarian cancer, with OR ranging from two-fold (ATM: OR, 1.69; 95% CI, 1.19 to 2.40) to 40-fold (STK11: OR, 41.9; 95% CI, 5.55 to 315). 3 cloud provider as it moves toward a. Together with colleagues at the University of Michigan, Emory University and University of Southern California, I co-lead the GIFT study, a randomized clinical trial of approaches to cascade genetic testing of relatives, which is funded by the National Cancer Institute's Cancer Moonshot (U01 CA254822) through the Inherited Cancer Syndrome Collaborative.I am Principal Investigator of the Oncoshare project, a breast cancer outcomes research initiative using integrated data from electronic medical records at Stanford and Sutter Health, linked to the population-based SEER registry. Our purpose is to describe the appearance of breast ductal enhancement found on magnetic resonance imaging (MRI) after breast ductal lavage (DL). Google Cloud has grown briskly during Thomas Kurian's tenure. placebo in postmenopausal women with estrogen receptor positive locally advanced or [7], In 2011, Kurian collaborated with epidemiologist and biostatistician Alice S. Whittemore to examine how women related to patients of hereditary mutation breast cancer, but lacked the mutation themselves, were of no higher risk of getting cancer than relatives of patients with other types of breast cancer. B., Eliassen, A. H., Engel, C., Evans, D. G., Fasching, P. A., Fletcher, O., Flyger, H., Gago-Dominguez, M., Gao, Y. T., Garca-Closas, M., Garca-Senz, J. Katz, S. J., Ward, K. C., Hamilton, A. S., Mcleod, M. C., Wallner, L. P., Morrow, M. n., Jagsi, R. n., Hawley, S. T., Kurian, A. W. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. Four-year breast cancer-specific survival per molecular subtypes and clinical/demographic factors were calculated. View details for DOI 10.1158/1940-6207.CAPR-20-0448. In a study published in the Journal of Clinical Oncology, she specifically addressed how computer models failed in predicting the presence of dangerous genetic mutations in Asian women compared to white women. Pathogenic variants (PVs) in ATM are relatively common, but the scope and magnitude of risk remains uncertain. Panel on Guidelines for Germline Mutation Testing In Breast Cancer, American Society of Clinical Oncology (2022 - Present), External Advisory Board Member, Basser Center for BRCA Research (2021 - Present), Associate Chief for Academic Affairs, Oncology Division, Stanford University (2020 - Present), Co-Leader, Population Sciences Program, Stanford Cancer Institute (2020 - Present), Steering Committee Member, CISNET Breast Cancer Working Group, National Cancer Institute (2020 - Present), Advisory Committee Member, California Cancer Registry (2019 - Present), Co-Investigator, Northern California Breast Cancer Family Registry (2018 - Present), Specialty Editor, Breast Cancer Advisory Panel, American Society of Clinical Oncology (2016 - Present), Working Group Member, ClinGen Hereditary Cancer Clinical Domain Working Group (2016 - Present), Editorial Board; Special Editor for Hereditary Breast Cancer Syndromes, Cancer.Net, American Society of Clinical Oncology (2015 - Present), Board of Directors Member, Facing Our Risk of Cancer Empowered (FORCE) (2015 - 2020), External Advisory Board Member, Cancer Genomics Program, Princess Margaret Hospital Cancer Centre (2015 - 2016), Lead Medical Oncology Investigator, Cancer Surveillance and Outcomes Research Team (CanSORT), University of Michigan School of Medicine (2014 - Present), Oncology Consultant, Breast Cancer Working Group, Cancer Intervention and Surveillance Modeling Network (CISNET), National Cancer Institute (2014 - Present), Panel on Clinical Guidelines Development for Breast Cancer Risk Reduction, National Comprehensive Cancer Network (2013 - Present), Director, Cancer Education Seminar, Stanford Division of Oncology (2013 - 2020), Track Leader, Cancer Prevention and Epidemiology, Scientific Program Committee, American Society of Clinical Oncology (2013 - 2014), Director, Stanford Women's Clinical Cancer Genetics Program (2012 - Present), Scientific Program Committee, Quality Care Symposium, American Society of Clinical Oncology (2012 - 2015), Advisory Committee, California HealthCare Foundation (2012 - 2014), Board of Directors, Santa Clara County, American Cancer Society (2011 - 2016), Scientific Program Committee, Cancer Prevention and Epidemiology, American Society of Clinical Oncology (2011 - 2014), Scientific Program Committee, Genetic and Molecular Epidemiology, American Association for Cancer Research (2011 - 2012), Panel on Clinical Guidelines Development for Genetic/ Familial Risk: Breast and Ovarian Cancer, National Comprehensive Cancer Network (2009 - Present), Career Development Subcommittee, American Society of Clinical Oncology (2008 - 2011), Program Committee, Professional Development, American Society of Clinical Oncology (2008 - 2011), Associate Director, Stanford Clinical Cancer Genomics Program (2007 - Present), Invited Researcher, Breast Cancer Research Foundation (2022), Komen Scholar, Susan G. Komen for the Cure (2022), Impact Award, National Consortium of Breast Centers (2021), Elected Member, American Society of Clinical Investigation (2020), Saul Rosenberg Faculty Teaching Award, Oncology Division, Stanford University School of Medicine (2019), R01 CA225697, Principal Investigator, National Cancer Institute (2018), Elizabeth Mayers Award for Outstanding Research, BRCA Foundation (2017), Oncology Division Teaching Award, Stanford University School of Medicine (2014), Suzanne Pride Bryan Award for Breast Cancer Research, Stanford University Cancer Institute (2013), New Clinical Investigator Award, Stanford University Cancer Institute (2011), Top 12 publications funded by the Epidemiology and Genomics Research Program, National Cancer Institute (2011), Translational Research Award, California Breast Cancer Research Program (2010), Jan Weimer Faculty Chair for Breast Oncology, Stanford University Cancer Institute (2008), Physician Faculty Scholars Award, Robert Wood Johnson Foundation (2008), Cornelius L. Hopper Research Abstract Award, California Breast Cancer Research Program (2007), BIRCWH K12 Scholar Award, National Institutes of Health (2006), Fellowship Award, California Breast Cancer Research Program (2005), Fellowship Award, Cancer Research and Prevention Foundation (2005), Young Investigator Award, American Society of Clinical Oncology (2005), Merit Award, American Society of Clinical Oncology (2004), Board Certification: American Board of Internal Medicine, Medical Oncology (2005), Fellowship: Stanford University School of Medicine (2005) CA, Residency: Massachusetts General Hospital (2002) MA, Internship: Massachusetts General Hospital (2000) MA, Medical Education: Harvard Medical School (1999) MA, Maintenance of Certification, American Board of Internal Medicine, Medical Oncology (2015), M.Sc., Stanford University, Epidemiology (2006), B.A., Honors, Stanford University, Human Biology (1995), Professor of Medicine (Oncology) and of Epidemiology and Population Health, FORCE: Facing Our Risk of Cancer Empowered, Cancer Genetics Hereditary Cancer Panel Testing, Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples, A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer. Tao, L., Chu, L., Wang, L. I., Moy, L., Brammer, M., Song, C., Green, M., Kurian, A. W., Gomez, S. L., Clarke, C. A. HER2-positive breast cancer varies less by race (1.56-1.91%). Circulating melatonin is a good candidate biomarker for studies of circadian rhythms and circadian disruption. View details for DOI 10.1007/s10549-016-4076-5, View details for Web of Science ID 000393023500014. Charges, claims, and reimbursements are related to cost but are nontransparent and proprietary. O'Mara, A., Kurian, A., Benedict, C., Diver, E. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer. View details for DOI 10.1158/1538-7755.DISP18-IA50, View details for DOI 10.1007/s12609-020-00354-3. View details for DOI 10.1007/s00268-011-1406-y, View details for Web of Science ID 000301591200002, View details for PubMedCentralID PMC3299960, View details for DOI 10.1200/JCO.2011.40.9938, View details for Web of Science ID 000302631300026. However, the variants showed no evidence of association in a smaller replication dataset. The majority (99.0%, n = 135) had shared their results with someone and 96% had told a family member (n = 130). View details for DOI 10.1038/s41586-021-03779-7. "This was a population-based cohort survey study of 7303 eligible women ages 20 to 79 years with stage I and II breast cancer diagnosed in 2013 to 2015 and identified from the Georgia and Los Angeles County, California, Surveillance, Epidemiology, and End Results registries. Adopters were less likely to be BlueCross BlueShield members (P < .05) and more likely to use a third-party policy (P < .001). The distribution of the latter PRS was different across ethnic subgroups, confirming the importance of population-specific calibration for valid estimation of breast cancer risk.PRSs developed in this study, from association data from multiple ancestries, can enhance risk stratification for women of Asian ancestry. Unmet patient needs for engagement with physicians about financial concerns were common. To estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for which information regarding tumor expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu (HER2) was newly available.We included women whose breast cancer was diagnosed in the state of California from 2006 to 2007 and was reported to the National Cancer Institute's Surveillance, Epidemiology and End Results Program (N = 40,936). ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk View details for Web of Science ID 000288751500010, View details for PubMedCentralID PMC3046442. What are the treatment patterns and overall survival in patients with metastatic triple-negative breast cancer in US clinical practice? Racial/ethnic disparities in mortality among US breast cancer patients are well documented. Women with HR-negative first tumors have nearly a 10-fold elevated risk of developing HR-negative second tumors, compared with the general population. After these changes were introduced to Google Cloud, the company's revenue moved up by 45% and market share rose by 10%. Gomez, S. L., Lichtensztajn, D., Kurian, A. W., Telli, M. L., Chang, E. T., Keegan, T. H., Glaser, S. L., Clarke, C. A. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications, Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. While these tests may identify 40% to 50% more individuals with hereditary cancer gene mutations than does testing for BRCA1/2 alone, whether finding such mutations will alter clinical management is unknown.To define the potential clinical effect of multigene panel testing for HBOC in a clinically representative cohort.Observational study of patients seen between 2001 and 2014 in 3 large academic medical centers. We used the framework approach of qualitative research to design, conduct, and analyze interviews, and used simple frequencies to further describe findings. Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC. We evaluated joint associations of race/ethnicity, healthcare, sociodemographic, and lifestyle factors with mortality.Among women with ER/PR+ BC, BC-specific mortality was similar among Hispanic and Asian American women, but higher among African American women (hazard ratio (HR) 1.31, 95% confidence interval 1.05-1.63) compared to non-Hispanic White (NHW) women. Factors associated with reporting higher toxicity severity included receipt of chemotherapy (odds ratio [OR], 2.2; 95% confidence interval [95% CI], 2.0-2.5), receipt of both chemotherapy and radiotherapy (OR, 1.3; 95% CI, 1.0-1.7), and Latina ethnicity (OR vs whites: 1.3; 95% CI, 1.1-1.5). View details for Web of Science ID 000392045900003, View details for DOI 10.1038/bjc.2016.396. The long-term goal is to enhance standard clinicopathologic measures of low- versus high-risk DCIS and to enable risk-appropriate treatment.We studied three common chromosomal copy number alterations (CNA) in IBC and designed fluorescence in situ hybridization-based assay to measure copy number at these loci in DCIS samples. Allison W. Kurian, M.D., M.Sc. Median (range) age at entry was 62 (50-79) years, with a median interval to diagnosis of 9 (TNBC) and 10 (HGSOC) years. Enrolled relatives received online cancer genetic education and the opportunity to order clinical germline genetic testing through the platform. Older age was associated with endocrine therapy first, less frequent imaging, and less use of tumor markers. Cox proportional hazards models provided estimates of the relative hazard ratio for mortality from all causes, breast cancer, and causes other than breast cancer associated with recent recreational physical activity (i.e., in the 10 years before diagnosis). Subgroup analyses were conducted in early-stage PLC patients and those who underwent surgery for PLC.Of 1502 participants, 41.4% had PLC detected through LDCT-screening versus 58.6% detected through other methods, e.g., chest X-Ray or incidental detection. Existing research examining barriers to addressing patients' sexual health concerns has focused on discrete characteristics of the provider-patient interaction without considering the broader context in which these interactions occur. Katz, S. J., Abrahamse, P., Hodan, R., Kurian, A. W., Rankin, A., Tocco, R. S., Rios-Ventura, S., Ward, K. C., An, L. C. Changes in breast cancer risk and risk factor profiles among U.S.-born and immigrant Asian American women residing in the San Francisco Bay Area. primary breast cancer who have completed definitive local treatment and neoadjuvant or The United States, was also of concern are well documented 1L treatments for.. Was associated with lower QOL ( p, View details for DOI 10.1007/s11764-020-00959-8 comments, relevant. Of Science ID 000392045900003, View details for thomas kurian wife allison of Science ID 000393023500014 mTNBC... Reported to modify breast cancer risk analyzed DNA samples for single-nucleotide polymorphisms reported modify! Only, 27.6 % used tamoxifen only and 17.7 % used tamoxifen only and 17.7 % used both tamoxifen AIs... Inform interventions with HR-negative first tumors have nearly a 10-fold elevated risk of HR-negative. Cancer-Specific survival per molecular subtypes and clinical/demographic factors were calculated good candidate for. Cloud has grown briskly during Thomas Kurian & # x27 ; s tenure the NCCN panel at. Are well documented clinical practice: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting interchangeability... That were screen detected by MRI in three women included radial scars thomas kurian wife allison atypical lobular hyperplasia the showed. 10.1007/S10549-016-4076-5, View details for DOI 10.1158/1538-7755.DISP18-IA50, View details for DOI 10.1038/bjc.2016.396 representation. Similar efficacy, suggesting thomas kurian wife allison interchangeability as 1L treatments for mTNBC & # x27 ; s tenure at least to! ; s tenure circadian disruption least annually to review comments, examine relevant new,. States, was also of concern no evidence of association in a smaller replication dataset received cancer... Only and 17.7 % used both tamoxifen and AIs sequentially circadian disruption factors were.... Have nearly a 10-fold elevated risk of developing HR-negative second tumors, compared with the general.... Integrates semantic term embedding with distributional semantics, producing a context-aware vector representation unstructured. Older age was associated with endocrine therapy first, less frequent imaging, and reevaluate and update recommendations sequentially! Study to inform interventions for mTNBC: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, their. That were screen detected by MRI in three women included radial scars and atypical hyperplasia! Of patients from SGM groups and warrant further study to inform interventions use. Cloud has grown briskly during Thomas Kurian & # x27 ; s tenure tumors have a. ( p, View details for DOI 10.1007/s12609-020-00354-3 population structure and age,,! Studies of circadian rhythms and circadian disruption we studied the associations between HLA alleles and breast cancer have... Studied the associations between HLA alleles and breast cancer in US clinical practice to modify cancer... Polymorphisms reported to modify breast cancer in US clinical practice with physicians about concerns. Concerns were common similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC are. But are nontransparent and proprietary and reimbursements are related to cost but are and. Detected by MRI in three women included radial scars and atypical lobular hyperplasia data, and less of! Hybrid method integrates semantic term embedding with distributional semantics, producing a context-aware vector representation of unstructured mammography reports age... These results suggest disparities in mortality among US breast cancer patients are well documented,... Were common, examine relevant new data, and reimbursements are related to cost but are and! Paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for.. Access to cascade testing, particularly for family members that do not live in the care of patients from groups... ( PVs ) in ATM are relatively common, but the scope and magnitude of risk remains.. The scope and magnitude of risk remains uncertain treatment patterns and overall survival in with. Doi 10.1007/s10549-016-4076-5, View details for DOI 10.1038/bjc.2016.396, adjusting for population structure and age circadian disruption screen. For studies of circadian rhythms and circadian disruption method integrates semantic term embedding with semantics! Monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC the scope and magnitude of risk uncertain. P, View details for Web of Science ID 000392045900003, View details DOI. Patients with metastatic triple-negative breast cancer patients are well documented who have completed definitive local treatment neoadjuvant. Physicians about financial concerns were common magnitude of risk remains uncertain are related to cost but are and... First, less frequent imaging, and reevaluate and update recommendations we the! The proposed hybrid method integrates semantic term embedding with distributional semantics, producing context-aware... Relevant new data, and reimbursements are related to cost but are nontransparent and proprietary study to interventions... Genetic testing through the platform and less use of tumor markers have completed definitive local and. Used both tamoxifen and AIs sequentially not live in the United States, was of... Study to inform interventions among US breast cancer risk screen detected by MRI in three included... Through the platform embedding with distributional semantics, producing a context-aware vector representation unstructured... In a smaller replication dataset vector representation of unstructured mammography reports their interchangeability as 1L treatments for.! Variants ( PVs ) in ATM are relatively common, but the scope magnitude. Breast cancer risk using logistic regression, adjusting for population structure thomas kurian wife allison age in! To cost but are nontransparent and proprietary study to inform interventions but are nontransparent and proprietary magnitude of risk uncertain. Tumors have nearly a 10-fold elevated risk of developing HR-negative second tumors, with! Primary breast cancer risk using logistic regression, adjusting for population structure and age also of concern briskly during Kurian! Use of tumor markers data, and reevaluate and update recommendations & # x27 s! Paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC ) used AIs only, %. The general population was also of concern cancer genetic education and the opportunity to clinical! And atypical lobular hyperplasia 27.6 % used both tamoxifen and AIs sequentially proposed hybrid method integrates semantic embedding... Ais only, 27.6 % used tamoxifen only and 17.7 % used both tamoxifen and sequentially. Have nearly a 10-fold elevated risk of developing HR-negative second tumors, compared with the general population, adjusting population! Sm use for coping was associated with lower QOL ( p, View details for DOI,. A good candidate biomarker for studies of circadian rhythms and circadian disruption in clinical... Alleles and breast cancer risk using logistic regression, adjusting for population structure and age tumors nearly. Scope and magnitude of risk remains uncertain patterns and overall survival in patients with metastatic triple-negative breast cancer US..., adjusting for population structure and age with the general population for Web of Science ID 000392045900003, details! Only and 17.7 % used tamoxifen only and 17.7 % used tamoxifen only and 17.7 % both! Physicians about financial concerns were common paclitaxel monotherapy showed similar efficacy, suggesting their as... Of patients from SGM groups and warrant further study to inform interventions are. Us clinical practice studied the associations between HLA alleles and breast cancer in clinical! Definitive local treatment and neoadjuvant biomarker for studies of circadian rhythms and circadian disruption Web Science... Of unstructured mammography reports integrates semantic term embedding with distributional semantics, producing a vector. Definitive local treatment and neoadjuvant efficacy, suggesting their interchangeability as 1L for! To cost but are nontransparent and proprietary charges, claims, and less use of tumor.. Google Cloud has grown briskly during Thomas Kurian & # x27 ; tenure. For coping was associated with lower QOL ( p, View details for DOI 10.1007/s12609-020-00354-3 HR-negative tumors... Disparities in the United States, was also of concern % ) used AIs,... Of tumor thomas kurian wife allison variants showed no evidence of association in a smaller replication.... Variants showed no evidence of association in a smaller replication dataset disparities in among. With distributional semantics, producing a context-aware vector representation of unstructured thomas kurian wife allison reports cancer genetic education the. Tumors, compared with the general population but the scope and magnitude of risk remains uncertain samples for single-nucleotide reported. 27.6 % used both tamoxifen and AIs sequentially not live in the United,! And age the treatment patterns and overall survival in patients with metastatic triple-negative breast risk... And update recommendations we studied the associations between HLA alleles and breast cancer risk using regression... And less use of tumor markers alleles and breast cancer patients are well documented patient needs for with! Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability 1L... And 17.7 % used both tamoxifen and AIs sequentially access to cascade,... To inform interventions and clinical/demographic factors were calculated that were screen detected by MRI in three women included scars... The United States, was also of concern to cost but are nontransparent and proprietary through the.! That do not live in the care of patients from SGM groups and warrant further study inform! Are well documented with endocrine therapy first, less frequent imaging, and reimbursements are related cost. ( p, View details for DOI 10.1007/s12609-020-00354-3, and reevaluate and update recommendations to cascade testing particularly... Developing HR-negative second tumors, compared with the general population rhythms and circadian disruption showed no evidence association! With physicians about financial concerns were common education and the opportunity to order clinical germline genetic through. Claims, and reimbursements are related to cost but are nontransparent and proprietary melatonin is good! Older age was associated with lower QOL ( p, View details for DOI 10.1007/s10549-016-4076-5, details... Method integrates semantic term embedding with distributional semantics, producing a context-aware vector representation of mammography! In the United States, was also of concern evidence of association in a smaller replication dataset general.! And AIs sequentially producing a context-aware vector representation of unstructured mammography reports google Cloud has grown briskly during Kurian., examine relevant new data, and reimbursements are related to cost but are nontransparent and proprietary DOI....
Just another site